Formulary Search Results for: CALCIUM AND VITAMIN D
6.1.2.2 SGLT2 Inhibitors - View Category
Restrictions:
Restricted to use only in adult patients for whom a combination of dapagliflozin and metformin is appropriate and who have demonstrated compliance issues with the separate constituents.
Prescribing Notes:
NHSGGC Diabetes Guidelines click here
7.3.2.1 Oral progestogen-only contraceptives - View Category
7.4.1 Drugs for urinary retention - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Only suitable for patients with enlargement of the prostate.
7.1.1.0 Prostaglandins and oxytocics - View Category
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following indications:
- Lung cancer:
- As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 (programmed cell death ligand 1) on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.
- In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
- Biliary tract cancer: In combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer.
- Endometrial cancer: In combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:
- durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
- durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
- Liver cancer: In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).
10.2.2 Skeletal muscle relaxants - View Category
10.2.2 Skeletal muscle relaxants - View Category
10.2.2 Skeletal muscle relaxants - View Category
Restrictions:
Restricted to specialist use for treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Prescribing Notes:
Patients commencing treatment should be reviewed via a formal assessment conducted by the specialist service at 4 weeks. Treatment should be discontinued at that point if a clinically significant improvement is not seen. Patients should also continue to be reviewed regularly thereafter to ensure continuing benefit.
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for:
- Monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.
- In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
Prescribing Notes:
Non-formulary indications that have not been recommended by SMC for use in NHS Scotland:
- In combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in accordance with the prescribing notes below.
Prescribing Notes:
Psoriasis in adults:
- The treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systematic therapies including ciclosporin, methotrexate and psoralen and UVA treatment (PUVA) is restricted to specialist use. Continued treatment should be restricted to patients who achieve a PASI 75% response within 16 weeks.
Psoriasis in adolescents:
- The treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies is restricted to specialist use. Continued treatment should be restricted to patients who achieve at least 75% improvement in their Psoriasis Area and Severity Index (PASI 75) within 16 weeks.
Ustekinumab should be prescribed by brand name. Wezenla® is the preferred biosimilar.
For use in psoriatic arthritis see section 10.1.3.